Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma
Background. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the...
Saved in:
Main Authors: | Shinya Ohata, Kei Takenaka, Daisuke Sugiyama, Takeshi Sugimoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2022/3688727 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
by: Claudio Fozza, et al.
Published: (2011-01-01) -
Lymphoid Infiltrates in B Cell Non Hodgkin’s Lymphoma: Comparing Nuclear Characteristics between Lymph Node and Bone Marrow; and Evaluating Diagnostic Features of Bone Marrow Infiltrates in Paraffin Embedded Tissues
by: Mark H. Deverell, et al.
Published: (1997-01-01) -
A Rare Case of Immunotactoid Glomerulopathy Associated with Hodgkin Lymphoma
by: Keiki Nagaharu, et al.
Published: (2021-01-01) -
Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma
by: Sun Hee Chang, et al.
Published: (2015-01-01) -
A Case of Coronary Vasospasm after Repeat Rituximab Infusion
by: Calvin Ke, et al.
Published: (2015-01-01)